How to Cite
Abstract
Migraine is a prevalent, chronic and episodic neurological disease that is associated with a great worldwide burden of disability. Currently, the treatment for migraine implies a multiple and comprehensive approach to abortive, preventive and bio-behavioral medications, but since this is a polygenic disease with a shortage of treatments, it generates the need to investigate new therapies. It has been prooved that the calcitonin related peptide gene has great importance in the pathophysiology of this disease. Its pharmacological decrease has a great clinical impact on the lives of affected patients, which is why today the role of this gene is part of the main lines of research in migraine.
Keywords
References
Ashina M, Dodick D, Goadsby PJ, Reuter U, Silberstein S, Zhang F, Gage JR, Cheng S, Mikol DD, Lenz RA. Erenumab (AMG 334) in episodic migraine. Neurology. 2017 08 23;89(12):1237 1243. https://doi.org/10.1212/wnl.0000000000004391
Cernuda-Morollon E, Larrosa D, Ramon C, Vega J, Martinez-Camblor P, Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013 08 23;81(14):1191-1196. https://doi.org/10.1212/wnl.0b013e3182a6cb72
Riesco N, Cernuda-Morollón E, Pascual J. Neuropeptides as a Marker for Chronic Headache. Current Pain and Headache Reports. 2017 03 09;21(4). https://doi.org/10.1007/s11916-017-0618-8
Comité de Clasificación de Dolor de Cabeza de la International Headache Society (IHS) La Clasificación Internacional de Trastornos de Dolor de Cabeza, 3ª edición. Cefalalgia 2018; 38 (1): 1-211.
Benarroch EE. CGRP: Sensory neuropeptide with multiple neurologic implications. Neurology. 2011 07 18;77(3):281- 287. https://doi.org/10.1212/wnl.0b013e31822550e2
Russo AF. Calcitonin Gene-Related Peptide (CGRP): A New Target for Migraine. Annual Review of Pharmacology and Toxicology. 2015 01 06;55(1):533-552. https://doi.org/10.1146/annurev-pharmtox-010814-124701
Brain SD, Grant AD. Vascular Actions of Calcitonin Gene-Related Peptide and Adrenomedullin. Physiological Reviews. 2004 07;84(3):903-934. https://doi.org/10.1152/physrev.00037.2003
Negro A, Martelletti P. Gepants for the treatment of migraine. Expert Opinion on Investigational Drugs. 2019 05 17;28(6):555-567. https://doi.org/10.1080/13543784.2019.1618830
Santos-Lasaosa S, Belvís R, Cuadrado M, Díaz-Insa S, Gago-Veiga A, Guerrero-Peral A, Huerta M, Irimia P, Láinez J, Latorre G, Leira R, Pascual J, Porta-Etessam J, Sánchez del Río M, Viguera J, Pozo-Rosich P. CGRP en migraña: de la fisiopatología a la terapéutica. Neurología. 2019 07;. https://doi.org/10.1016/j.nrl.2019.03.013
Voss T, Lipton RB, Dodick DW, Dupre N, Ge JY, Bachman R, Assaid C, Aurora SK, Michelson D. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016 07 11;36(9):887-898. https://doi.org/10.1177/0333102416653233
Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ. Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine. New England Journal of Medicine. 2019 07 11;381(2):142 149. https://doi.org/10.1056/nejmoa1811090
Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. The Lancet. 2019 08;394(10200):737-745. https://doi.org/10.1016/s0140-6736(19)31606-x
Tepper SJ, Diener H, Ashina M, Brandes JL, Friedman DI, Reuter U, Cheng S, Nilsen J, Leonardi DK, Lenz RA, Mikol DD. Erenumab in chronic migraine with medication overuse. Neurology. 2019 04 17;92(20):e2309-e2320. https://doi.org/10.1212/wnl.0000000000007497
Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA. A Controlled Trial of Erenumab for Episodic Migraine. New England Journal of Medicine. 2017 Nov 30;377(22):2123-2132. https://doi.org/10.1056/nejmoa1705848
Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, Mueller M, Ahn AH, Schwartz YC, Grozinski-Wolff M, Janka L, Ashina M. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. The Lancet. 2019 09;394(10203):1030-1040. https://doi.org/10.1016/s0140-6736(19)31946-4
VanderPluym J, Dodick DW, Lipton RB, Ma Y, Loupe PS, Bigal ME. Fremanezumab for preventive treatment of migraine. Neurology. 2018 08 17;91(12):e1152-e1165. https://doi.org/10.1212/01.wnl.0000544321.19316.40
Ford JH, Ayer DW, Zhang Q, Carter JN, Leroux E, Skljarevski V, Aurora SK, Tockhorn-Heidenreich A, Lipton RB. Two randomized migraine studies of galcanezumab. Neurology. 2019 07 03;93(5):e508-e517. https://doi.org/10.1212/wnl.0000000000007856
Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine. Neurology. 2018 Nov 16;91(24):e2211-e2221. https://doi.org/10.1212/wnl.0000000000006640